You are here

Available in: English

Access to medicines and incentives for innovation: The balance struck in the Trans-Pacific Partnership (TPP) on intellectual property (patent and data exclusivity) protection for pharmaceutical products

Publication cover
Author: Artecona, Raquel - Plank-Brumback, Rosine M. UN symbol.: LC/L.4248 55 p. Editorial: ECLAC November 2016


This study addresses the balance struck under the Trans-Pacific Partnership Agreement (TPPA) between the right to health and access to medicines and the need to maintain the economic incentives to spur innovation and research and development through intellectual property protection. The analysis focuses on the patent and data-related intellectual property protection provisions of the TPPA, specifically regarding pharmaceutical (small-molecule and biologic) products, including on patent duration, linkage and term extensions as well as clinical test data protection and market exclusivity.
Special attention is paid to the United States and its negotiating position with respect to those aspects of intellectual property rights, as it has been and remains the world’s principal demandeur for high intellectual property rights (IPR) standards in trade agreements, including the TPPA.

Table of contents

Abstract .-- Introduction .-- I. Key trends in the global, regional and U.S. pharmaceutical industries .-- II. Patent and regulatory data-related protection on pharmaceutical products in TPP .-- III. Congressional mandates on intellectual property protection on pharmaceutical products .-- IV. Conclusions.

Search publications

See publications list


Get ECLAC updates by email